• In early May 2026, Becton, Dickinson and Company named long-time executive Vitor Roque as executive vice president and chief financial officer, reported second-quarter sales of US$4,714 million with a net loss of US$311 million, and filed employee stock ownership plan-related shelf registrations totaling about US$787 million in common stock.
• The company also launched its BD CentroVena One Insertion System in the U.S., advanced its “New BD” strategy with the completed separation of its Biosciences & Diagnostic Solutions business, maintained its quarterly dividend at US$1.05 per share, and reported earnings and revenue ahead of analyst expectations, leading management to raise full-year adjusted EPS guidance.
• We’ll now examine how Roque’s permanent CFO appointment and the raised full-year earnings guidance affect the existing investment narrative for BD.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Becton Dickinson Investment Narrative Recap

To own BD, you need to believe it can convert its broad medtech portfolio and “New BD” simplification into steadier earnings, despite recent volatility. The key short term catalyst is management’s raised full year adjusted EPS guidance following a quarter that topped expectations, while the biggest risk is that margin pressure and one off items, reflected in the recent net loss, keep clouding headline results. Roque’s appointment as permanent CFO does not materially change that near term setup.

The launch of the BD CentroVena One Insertion System looks most relevant here because it speaks directly to BD’s product led growth narrative. CentroVena expands BD further into acute vascular access, where consumables and safety focused innovation can support more predictable revenue streams. How quickly offerings like CentroVena and the Pyxis Pro and Alaris integrations scale will matter for validating the higher earnings guidance and offsetting pressures in areas such as China and tariffs.

Yet beneath the raised guidance, investors should be aware that...

Becton Dickinson's narrative projects $20.8 billion revenue and $2.2 billion earnings by 2029. This implies a 1.8% yearly revenue decline and an earnings increase of about $0.4 billion from $1.8 billion today.

Uncover how Becton Dickinson's forecasts yield a $192.31 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts painted a far tougher picture, expecting BD revenue to shrink about 3.1% a year even as earnings reach roughly US$2.3 billion, reminding you that views on tariff, pricing and margin risks can diverge sharply and may shift again after this latest CFO move and guidance change.

Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth as much as 77% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Becton Dickinson research is our analysis highlighting 6 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.